Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Sulfation of N -acetylglucosamine (GlcNAc) moieties of glycans is a common modification that has been implicated in many biological and disease processes. Glycans having sulfate replaced by a stable analogue may find use as glycomimetic drugs. Here, we describe the synthesis of analogues of UDP-GlcNAc in which C-6 hydroxyl is replaced by a thiol or disulfide-protected thiol. It was found that UDP-GlcNAc-6-deoxy-6-SH is a donor substrate for GCNT1 and UDP-GlcNAc-6-deoxy-6-S-SMe for B3GnT2, allowing the preparation of glycopeptides and oligo-LacNAc derivatives having a GlcNAc-6-deoxy-6-S- R moiety, respectively. The disulfide can be reduced to a thiol, which can easily be oxidized to the corresponding sulfonates. Furthermore, oligosaccharides having a sulfonate or disulfide at C-6 are appropriate substrates for glycosyltransferases, providing access to a panel of glycomimetics. The sulfonates and several reference glycans and glycopeptides were printed as a glycan microarray that was used to examine binding selectivities of several lectins, Siglecs, and hemagglutinins of influenza A viruses. It was found that sulfonates can either be tolerated, enhance binding as in the case of Siglec-4, or abolish recognition as for Siglec-9. Molecular modeling studies of the complex of Siglec-4 with sulfated and sulfonated sialyl LacNAc indicate that plasticity of the binding site of the protein and a great charge on oxygens of a sulfonate are responsible for the higher binding affinity. Introduction of a 6-sulfonate gives better step economy than conventional enzymatic sulfation, is simpler to operate, provides compounds resistant to hydrolysis by sulfatases, and can modulate binding selectivities.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: